Frederic Wohlwend to take over as CIO of Merck KGaA

Will replace Kai Beckman, who moves to global human resources

Frederic Wohlwend will take over as chief information officer (CIO) of Merck KGaA on 1 April, succeeding Kai Beckmann, who will join the Merck executive board with responsibility for global human resources on that date. Wohlwend will report directly to chairman Karl-Ludwig Kley.

Wohlwend has been senior vice president, information services for Merck’s Chemicals business, which includes the Performance Materials and Merck Millipore divisions.

Prior to this, he was senior vice president, information services for Merck’s Pharmaceuticals business, which includes the Merck Serono and Consumer Health Care divisions.

Wohlwend joined Merck in 2007 with the acquisition of the Swiss biotech pharmaceutical company Serono SA. He joined Serono in 1991 and held positions of increasing responsibility, latterly as CIO.

You may also like

Sustainability

Merck launches first bio-based HPLC solvent portfolio with lower CO2 emissions than fossil-fuel alternatives

The new patent-pending portfolio of renewable solvents for high-performance liquid chromatography offers replacements for acetonitrile, methanol and ethanol that reduce carbon emissions while maintaining performance
Research & Development

Merck and Moderna announce 5-year data for intismeran autogene in combination with KEYTRUDA

Eight Phase II and Phase III clinical trials are under way across multiple tumour types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma
Manufacturing

Merck Life Science announces closure of Arklow facility

Merck has said it will close the plant in Co Wicklow, Ireland, by the end of 2028, with the loss of 100 jobs
Analysis

Merck and others pull back from UK: what it means for pharma manufacturing

With pharma giant Merck pulling its own version of Brexit, what can the UK do to retain its drug manufacturing capabilities?
Research & Development

Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness

The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Research & Development

Merck releases positive topline results from two Phase III CORALreef trials

Treatment with enlicitide decanoate triggered a clinically meaningful reduction in LDL cholesterol, highlighting its potential for managing atherosclerotic cardiovascular disease
Subscribe now